Arbutus Biopharma (ABUS) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 52.3% versus a gain of 0.0%. Over five years, ABUS leads with a +5.1% price change compared with -97.2% for JBIO. Jade Biosciences is the larger company by market cap ($875.7 million vs $657.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | JBIO |
|---|---|---|
| Share price | $4.29 | $13.77 |
| Market cap | $657.55M | $875.74M |
| 1-day change | -4.24% | +2.68% |
| YTD return | -10.81% | -10.76% |
| 1-year return | 0.00% | +52.32% |
| 5-year return | +5.15% | -97.22% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $28.00 |
| 52-week low | $3.50 | $8.36 |
| Distance from 52-week high | -21.28% | -50.82% |
| Average volume | 4.65M | 887.52K |
| Shares outstanding | 153.28M | 63.60M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed ABUS by 52.3 percentage points over the past year.
ABUS vs JBIO FAQ
Which is bigger, Arbutus Biopharma or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $875.74M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or JBIO?
JBIO returned +52.32% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.